Title: Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined
with chemotherapy when treating advanced gastric cancer
Version: 0 Date: 05 Sep 2023
Reviewer's report:
Major comments:
1. The authors should first clarify the number of patients included. In the Abstract section:
‘Sixty-eight patients with advanced gastric cancer treated in our hospital from January 2020 to
December 2021 were randomly divided into study group (n = 45) and control group (n = 45).’
Therefore, 68 patients or 90 patients?
2. In the Results section, the authors stated that the deadline for follow-up was December 31,
2021. However, the authors included advanced GC patients in their hospital from January 2020
to December 2021.
3. In the General Information section: ‘In the research group, there were 20 males and 14
females.’ However, 45 patients were in the research group.
4. Table 1: DCR = CR+PR+SD? ORR = CR+PR? The ORR and DCR data were wrong.
5. Apatinib is a targeted agent rather than a chemotherapy agent. The main conclusion of this
manuscript was that PD-1 inhibitor combined with chemotherapy has been more effective when
treating patients with advanced GC. The conclusion was improper.
6. Table 7: The data were wrong. What were the other adverse events? Detailed grading should
be specified according to adverse events reporting requirements.
Based on the above alone, I lack confidence in the data in this manuscript. Publication seems
impossible unless the authors make convincing revisions.
Minor comments:
1. Were Figures 2 and 3 original to the authors?
2. Abbreviations were not used correctly in many parts of the manuscript.
Title: Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined
with chemotherapy when treating advanced gastric cancer
Version: 0 Date: 05 Sep 2023
Reviewer's report:
Major comments:
1. The authors should first clarify the number of patients included. In the Abstract section:
‘Sixty-eight patients with advanced gastric cancer treated in our hospital from January 2020 to
December 2021 were randomly divided into study group (n = 45) and control group (n = 45).’
Therefore, 68 patients or 90 patients?
2. In the Results section, the authors stated that the deadline for follow-up was December 31,
2021. However, the authors included advanced GC patients in their hospital from January 2020
to December 2021.
3. In the General Information section: ‘In the research group, there were 20 males and 14
females.’ However, 45 patients were in the research group.
4. Table 1: DCR = CR+PR+SD? ORR = CR+PR? The ORR and DCR data were wrong.
5. Apatinib is a targeted agent rather than a chemotherapy agent. The main conclusion of this
manuscript was that PD-1 inhibitor combined with chemotherapy has been more effective when
treating patients with advanced GC. The conclusion was improper.
6. Table 7: The data were wrong. What were the other adverse events? Detailed grading should
be specified according to adverse events reporting requirements.
Based on the above alone, I lack confidence in the data in this manuscript. Publication seems
impossible unless the authors make convincing revisions.
Minor comments:
1. Were Figures 2 and 3 original to the authors?
2. Abbreviations were not used correctly in many parts of the manuscript.
Please review this paper.
user
Title: Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined
with chemotherapy when treating advanced gastric cancer
Version: 0 Date: 05 Sep 2023
Reviewer's report:
Major comments:
1. The authors should first clarify the number of patients included. In the Abstract section:
‘Sixty-eight patients with advanced gastric cancer treated in our hospital from January 2020 to
December 2021 were randomly divided into study group (n = 45) and control group (n = 45).’
Therefore, 68 patients or 90 patients?
2. In the Results section, the authors stated that the deadline for follow-up was December 31,
2021. However, the authors included advanced GC patients in their hospital from January 2020
to December 2021.
3. In the General Information section: ‘In the research group, there were 20 males and 14
females.’ However, 45 patients were in the research group.
4. Table 1: DCR = CR+PR+SD? ORR = CR+PR? The ORR and DCR data were wrong.
5. Apatinib is a targeted agent rather than a chemotherapy agent. The main conclusion of this
manuscript was that PD-1 inhibitor combined with chemotherapy has been more effective when
treating patients with advanced GC. The conclusion was improper.
6. Table 7: The data were wrong. What were the other adverse events? Detailed grading should
be specified according to adverse events reporting requirements.
Based on the above alone, I lack confidence in the data in this manuscript. Publication seems
impossible unless the authors make convincing revisions.
Minor comments:
1. Were Figures 2 and 3 original to the authors?
2. Abbreviations were not used correctly in many parts of the manuscript.
assistant